OLD National Bancorp IN Grows Stock Position in Pfizer Inc. (NYSE:PFE)

OLD National Bancorp IN grew its stake in Pfizer Inc. (NYSE:PFE) by 12.0% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 225,102 shares of the biopharmaceutical company’s stock after buying an additional 24,165 shares during the quarter. OLD National Bancorp IN’s holdings in Pfizer were worth $6,481,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Adage Capital Partners GP L.L.C. raised its holdings in Pfizer by 40.5% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock worth $157,215,000 after purchasing an additional 1,365,295 shares during the period. LifePlan Financial LLC acquired a new position in shares of Pfizer during the 4th quarter worth approximately $255,000. Brookstone Capital Management lifted its position in shares of Pfizer by 88.5% during the 3rd quarter. Brookstone Capital Management now owns 452,352 shares of the biopharmaceutical company’s stock valued at $14,109,000 after buying an additional 212,369 shares in the last quarter. ETF Store Inc. increased its holdings in Pfizer by 12.0% in the 3rd quarter. ETF Store Inc. now owns 6,803 shares of the biopharmaceutical company’s stock worth $214,000 after acquiring an additional 727 shares in the last quarter. Finally, KLCM Advisors Inc. raised its position in Pfizer by 75.0% during the fourth quarter. KLCM Advisors Inc. now owns 173,793 shares of the biopharmaceutical company’s stock worth $5,004,000 after acquiring an additional 74,487 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Up 0.9 %

PFE stock traded up $0.24 during midday trading on Monday, hitting $26.24. The company’s stock had a trading volume of 5,802,217 shares, compared to its average volume of 41,924,066. The firm has a 50-day simple moving average of $27.11 and a 200-day simple moving average of $28.62. The firm has a market capitalization of $148.59 billion, a P/E ratio of 72.22, a PEG ratio of 1.17 and a beta of 0.61. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. Pfizer Inc. has a 52-week low of $25.23 and a 52-week high of $40.37.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The firm had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. During the same period last year, the business posted $1.14 earnings per share. Pfizer’s revenue was down 41.3% compared to the same quarter last year. As a group, equities analysts forecast that Pfizer Inc. will post 2.24 EPS for the current year.

Analysts Set New Price Targets

Several analysts have recently issued reports on PFE shares. TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research report on Thursday, January 4th. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Monday, April 15th. Finally, Guggenheim initiated coverage on Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective on the stock. Eleven investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, Pfizer currently has a consensus rating of “Hold” and a consensus target price of $36.33.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.